TY - JOUR
T1 - Development of risk prediction models for glioma based on genome-wide association study findings and comprehensive evaluation of predictive performances
AU - Zhao, Yingjie
AU - Chen, Gong
AU - Yu, Hongjie
AU - Hu, Lingna
AU - Bian, Yunmeng
AU - Yun, Dapeng
AU - Chen, Juxiang
AU - Mao, Ying
AU - Chen, Hongyan
AU - Lu, Daru
N1 - Funding Information:
This work was partially supported by Natural Science Foundation of China [81170786, 8132706, 81372235 and 81071739]; the Doctoral Fund of Ministry of Education of China [20110071110028]; the National Distinguish Young Scientists Foundation [81025013 to Y. M.]; the Project for National 985 Engineering of China [985III-YFX0102 to Y. M.]; and the “Dawn Tracking” Program of Shanghai Education Commission, China [10GG01 to Y. M.].
Publisher Copyright:
© Zhao et al.
PY - 2018
Y1 - 2018
N2 - Over 14 common single nucleotide polymorphisms (SNP) have been consistently identified from genome-wide association studies (GWAS) as associated with glioma risk in European background. The extent to which and how these genetic variants can improve the prediction of glioma risk has was not been investigated. In this study, we employed three independent case-control datasets in Chinese populations, tested GWAS signals in dataset1, validated association results in dataset2, developed prediction models in dataset2 for the consistently replicated SNPs, refined the consistently replicated SNPs in dataset3 and developed tailored models for Chinese populations. For model construction, we aggregated the contribution of multiple SNPs into genetic risk scores (count GRS and weighed GRS) or predicted risks from logistic regression analyses (PRFLR). In dataset2, the area under receiver operating characteristic curves (AUC) of the 5 consistently replicated SNPs by PRFLR(SNPs) was 0.615, higher than those of all GRSs(ranging from 0.607 to 0.611, all P>0.05). The AUC of genetic profile significantly exceeded that of family history (fmc) alone (AUC=0.535, all P<0.001). The best model in our study comprised "PRURA +fmc" (AUC=0.646) in dataset3. Further model assessment analyses provided additional evidence. This study indicates that genetic markers have potential value for risk prediction of glioma.
AB - Over 14 common single nucleotide polymorphisms (SNP) have been consistently identified from genome-wide association studies (GWAS) as associated with glioma risk in European background. The extent to which and how these genetic variants can improve the prediction of glioma risk has was not been investigated. In this study, we employed three independent case-control datasets in Chinese populations, tested GWAS signals in dataset1, validated association results in dataset2, developed prediction models in dataset2 for the consistently replicated SNPs, refined the consistently replicated SNPs in dataset3 and developed tailored models for Chinese populations. For model construction, we aggregated the contribution of multiple SNPs into genetic risk scores (count GRS and weighed GRS) or predicted risks from logistic regression analyses (PRFLR). In dataset2, the area under receiver operating characteristic curves (AUC) of the 5 consistently replicated SNPs by PRFLR(SNPs) was 0.615, higher than those of all GRSs(ranging from 0.607 to 0.611, all P>0.05). The AUC of genetic profile significantly exceeded that of family history (fmc) alone (AUC=0.535, all P<0.001). The best model in our study comprised "PRURA +fmc" (AUC=0.646) in dataset3. Further model assessment analyses provided additional evidence. This study indicates that genetic markers have potential value for risk prediction of glioma.
KW - Genetic risk score
KW - Genome wide association study
KW - Glioma
KW - Prediction risk from logistic regression analyses
KW - Risk prediction
UR - http://www.scopus.com/inward/record.url?scp=85041452987&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85041452987&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.10882
DO - 10.18632/oncotarget.10882
M3 - Article
AN - SCOPUS:85041452987
SN - 1949-2553
VL - 9
SP - 8311
EP - 8325
JO - Oncotarget
JF - Oncotarget
IS - 9
ER -